Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
The study was published in the journal Nature Cell Biology by senior author April Pyle, associate professor of microbiology, immunology and molecular genetics and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore dystrophin, the protein that is missing in the muscles of boys with Duchenne.
Without dystrophin, muscles degenerate and become progressively weaker. Duchenne symptoms usually begin in early childhood; patients gradually lose mobility and typically die from heart or respiratory failure around age 20. There is currently no way to reverse or cure the disease.
For years, scientists have been trying different methods that direct human pluripotent stem cells to generate skeletal muscle stem cells that can function appropriately in living muscle and regenerate dystrophin-producing muscle fibers. However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
“We have found that just because a skeletal muscle cell produced in the lab expresses muscle markers, doesn’t mean it is fully functional,” said Pyle. “For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.”
By analyzing human development, the researchers found a fetal skeletal muscle cell that is extraordinarily regenerative. Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the reserchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Once they were able to isolate skeletal muscle cells using the newly identified surface markers, the research team matured those cells in the lab to create dystrophin-producing muscle fibers. The muscle fibers they created were uniformily muscle cells, but the fibers were still smaller than those found in real human muscle.
“We were missing another key component,” said Michael Hicks, lead author of the study. The skeletal muscle cells were not maturing properly, he explained. “We needed bigger, stronger muscle that also had the ability to contract.”
Once again, the team looked to the natural stages of human development for answers. Hicks discovered that a specific cell signaling pathway called TGF Beta needs to be turned off to enable generation of skeletal muscle fibers that contain the proteins that help muscles contract. Finally, the team tested their new method in a mouse model of Duchenne.
“Our long term goal is to develop a personalized cell replacement therapy using a patient’s own cells to treat boys with Duchenne,” said Hicks. “So, for this study we followed the same steps, from start to finish, that we’d follow when creating these cells for a human patient.”
First, the Duchenne patient cells were reprogrammed to become pluripotent stem cells. The researchers then removed the genetic mutation that causes Duchenne using the gene editing technology CRISPR-Cas9. Using the ERBB3 and NGFR surface markers, the skeletal muscle cells were isolated and then injected into mice at the same time a TGF Beta inhibitor was administered.
“The results were exactly what we’d hoped for,” said Pyle. “This is the first study to demonstrate that functional muscle cells can be created in a laboratory and restore dystrophin in animal models of Duchenne using the human development process as a guide.”
Further research will focus on generating skeletal muscle stem cells that can respond to continuous injury and regenerate new muscle long-term using the team’s new isolation and maturation strategy.
The Latest on: Duchenne Muscular Dystrophy
- FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophyon August 11, 2020 at 4:20 am
FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids ...
- Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progresson August 10, 2020 at 4:15 pm
(NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business progress. “We remain on track for ...
- Dyne Therapeutics grabs $115M to ramp up muscle disease pipelineon August 10, 2020 at 6:54 am
Dyne Therapeutics is back at the VC well—this time, it’s raising $115 million to bankroll a pipeline of treatments for muscle diseases including its lead programs for Duchenne muscular dystrophy and ...
- Duchenne Muscular Dystrophy Treatment Market Size 2020 Global Growth, Trends, Industry Analysis, Key Players and Forecast to 2024on August 10, 2020 at 1:58 am
Global Duchenne Muscular Dystrophy Treatment Market research report is a meticulous investigation of current scenario ...
- FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Olderon August 7, 2020 at 10:54 am
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam) for treatment of spinal muscular ...
- Calf sale raises money for muscular dystrophy researchon August 3, 2020 at 3:49 am
Grant has Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle degeneration and weakness. “There’s no cure for Duchenne,” Paul explains. “Boys with it don’t make it out ...
- Global Duchenne Muscular Dystrophy Therapeutics Market 2020 Business Outlook with COVID-19 Scenario to 2025on August 2, 2020 at 12:07 pm
Global Duchenne Muscular Dystrophy Therapeutics Market 2020 by Company, Type and Application, Forecast to 2025 ...
- Community rallies around parents of boys with muscular dystrophyon August 2, 2020 at 2:00 am
A community in Roscommon is rallying around a couple whose two sons suffer from a rare genetic disease, Duchenne Muscular Dystrophy (DMD.) ...
- With JETT Ride 2020, Hains brothers continue fight against Duchenne MDon August 1, 2020 at 11:30 am
Luke and Lance Hains' commitment to their younger brother, Levi Hains, and those like him who are battling Duchenne Muscular Dystrophy, remains strong.
- A Year After Gene Therapy, Boys With Muscular Dystrophy Are Healthier and Strongeron July 30, 2020 at 7:00 am
The gene therapy given to the nine boys by Pfizer was actually developed by a research team at UNC—and it took over 30 years.
via Google News and Bing News